Chongqing Sintaho

Sintaho is a clinical-stage biopharmaceutical company headquartered in Chongqing, China, dedicated to the discovery and development of next-generation protein degraders. The company utilizes its advanced PROTAC (Proteolysis Targeting Chimera) technology platform to address unmet medical needs in oncology and autoimmune disorders. Its lead candidate, SH-001, is a potent BTK degrader currently in clinical trials for B-cell malignancies, designed to overcome resistance seen with traditional covalent BTK inhibitors. Sintaho's pipeline also includes programs targeting the androgen receptor and estrogen receptor for solid tumors. The company is backed by prominent venture capital firms and maintains a strong focus on innovative small-molecule drug discovery and targeted protein degradation.